Growth & profitability
- Revenue has declined 9.4% per year over the past 5 years.
Financial health
- Total debt has grown faster than revenue (297.9% vs -9.4% per year).
- Operating income covered interest expense -15.6× in the latest year.
CYRX Financials Cryoport, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $176M | $78M | 47.1% | -20.9% | -$25M | — | $250M |
| 2024 | $157M | -$115M | 44.4% | -77.6% | -$34M | — | $34M |
| 2023 | $169M | -$100M | 44.7% | -59.6% | -$40M | — | $35M |
| 2022 | $237M | -$37M | 43.8% | -13.4% | -$24M | — | $29M |
| 2021 | — | -$276M | — | — | -$16M | — | $139M |
| 2020 | — | -$33M | — | — | -$24M | — | $37M |
| 2019 | — | -$18M | — | — | -$7M | — | $47M |
| 2018 | — | -$10M | — | — | -$6M | — | $37M |
| 2017 | — | -$8M | — | — | -$5M | — | $15M |
| 2016 | — | -$13M | — | — | -$7M | — | $5M |
| 2016 | — | -$10M | — | — | — | — | $3M |
| 2015 | — | -$7M | — | — | — | — | $1M |
| 2014 | — | -$20M | — | — | — | — | $369581 |
| 2013 | — | -$6M | — | — | -$5M | $1M | $563104 |
| 2012 | — | -$8M | — | — | -$7M | $325325 | $5M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $48M | -$11M | 45.8% | -20.1% | -$6M | — | $273M |
| Dec '25 | $45M | -$12M | 47.8% | -22.1% | -$5M | — | $250M |
| Sep '25 | $44M | -$7M | 48.2% | -22.5% | -$1M | — | $256M |
| Jun '25 | $45M | $105M | 47.0% | -21.2% | -$12M | — | $243M |
| Mar '25 | $41M | -$12M | 45.4% | -17.5% | -$8M | — | $36M |
| Dec '24 | $41M | -$19M | 47.0% | -30.7% | -$11M | — | $34M |
| Sep '24 | $38M | $805000 | 45.5% | -34.9% | -$4M | — | $31M |
| Jun '24 | $40M | -$78M | 44.5% | -196.5% | -$12M | — | $34M |
| Mar '24 | $37M | -$19M | 40.4% | -46.9% | -$7M | — | $39M |
| Dec '23 | — | -$62M | — | — | -$9M | — | $35M |
| Sep '23 | — | -$13M | — | — | -$11M | — | $59M |
| Jun '23 | — | -$18M | — | — | -$13M | — | $67M |
| Mar '23 | — | -$6M | — | — | -$7M | — | $39M |
| Dec '22 | — | -$9M | — | — | -$4M | — | $29M |
| Sep '22 | — | -$5M | — | — | -$4M | — | $31M |
| Jun '22 | — | -$9M | — | — | -$12M | — | $37M |
| Mar '22 | — | -$13M | — | — | -$4M | — | $134M |
| Dec '21 | — | -$260M | — | — | -$6M | — | $139M |
| Sep '21 | — | -$7M | — | — | $25000 | — | $44M |
| Jun '21 | — | -$5M | — | — | -$1M | — | $60M |
Valuation over time
How the market has priced CYRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 6.2× (Dec '25) to 10.2× (Jun '26).
- The price-to-sales ratio has fallen from 5.1× (Mar '23) to 4.5× (Jun '26).
P/E
P/S
Frequently asked questions
Is CYRX growing its revenue and profit?
Over the past 5 years, Cryoport, Inc.'s revenue has declined 9.4% per year. These are computed facts, not advice.
How much debt does CYRX have?
As of FY2025, Cryoport, Inc. reported — of total debt against $250M of cash; operating income covered interest expense -15.6×.
What is CYRX's profit margin?
In FY2025, gross margin was 47.1%, operating margin -20.9%, and net margin 44.4%.
What is CYRX's P/E ratio?
As of Jun '26, Cryoport, Inc. traded at a price-to-earnings ratio of about 10.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.